This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Back
Filter 5 trials Clear all
Filter by:

A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

  • Status Recruiting
    Recruiting
  • Condition Multiple Myeloma
    Multiple Myeloma
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Drug: CC-92480, Drug: Bortezomib, Drug: Dexamethasone, Drug: Daratumumab, Drug: Carfilzomib, Drug: Elotuzumab, Drug: Isatuximab, Drug: Carfilzomib

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: CC-92480, Drug: Bortezomib, Drug: Dexamethasone, Drug: Daratumumab, Drug: Carfilzomib, Drug: Elotuzumab, Drug: Isatuximab, Drug: Carfilzomib

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Colorado Blood Cancer Institute, Denver, Colorado, United States

Brief Summary

This is an open-label, multicenter, Phase 1/2 study to determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D), and to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

  • Status Recruiting
    Recruiting
  • Condition Multiple Myeloma
    Multiple Myeloma
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Drug: CC-92480, Drug: Dexamethasone

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: CC-92480, Drug: Dexamethasone

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

City of Hope Cancer Center, Duarte, California, United States

Brief Summary

This is an open-label, multi-center, international, Phase 1/2 study to assess the safety, PK and efficacy of CC-92480 monotherapy and in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma (RRMM). RRMM patient previously treated with at least 3 prior regimens including lenalidomide or pomalidomide, a proteasome inhibitor and a CD38 antibody will be eligible.

A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male Participants

  • Status Not yet recruiting
    Not yet recruiting
  • Condition Healthy Volunteers
    Healthy Volunteers
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: [14C]-CC-92480

Eligibility
  • Ages: 18 to 55 Years (Adult)
  • Sexes: Male
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Drug: [14C]-CC-92480

Eligibility
  • Ages:
  • Sexes: Male
  • Accepts Healthy Volunteers:
Locations

Covance Clinical Research Unit Inc, Madison, Wisconsin, United States

Brief Summary

This is a single-center, open-label study to be conducted in healthy adult male participants. This study is designed to characterize the biotransformation and excretion of [14C]-CC-92480 and to evaluate the safety and tolerability of [14C]-CC-92480 following a single oral dose of [14C]-CC-92480.

Relative Bioavailability and PPI Effects of CC-92480 Test and Reference Formulations in Healthy Subjects

  • Status Completed
    Completed
  • Condition Healthy Volunteer
    Healthy Volunteer
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: Rabeprazole, Drug: CC-92480

Eligibility
  • Ages: 18 to 55 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Drug: Rabeprazole, Drug: CC-92480

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

PPD Phase 1 Clinic, Austin, Texas, United States

Brief Summary

This is a Phase 1, open-label, randomized, four-period, crossover study in healthy females of nonchildbearing potential and male subjects - to be conducted at a single center in the United States. The study will consist of a screening phase, a baseline phase, four treatment periods, and a follow-up phone call. The 4 treatment periods are divided into two pairs (Period 1 and 2 and Period 3 and 4), potentially separated by an intermission during which subjects will be discharged from the research unit: Periods 1 and 2 support relative bioavailability (RBA) estimation, while Periods 3 and 4 support estimation of PPI effects.

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single Ascending Doses of CC-92480 in Healthy Subjects

  • Status Completed
    Completed
  • Condition Healthy Volunteer
    Healthy Volunteer
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: CC-92480, Drug: CC-92480

Eligibility
  • Ages: 18 to 55 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Drug: CC-92480, Drug: CC-92480

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Covance-Daytona Beach, Daytona Beach, Florida, United States

Brief Summary

This is a two-part study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of CC-92480 and explore the effect of food on the bioavailability of CC-92480 in healthy subjects. Part 1: Part 1 is a single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and pharmacodynamics (PD) of CC-92480 following administration of single oral doses in healthy adult subjects. Part 1 will consist of escalating single doses in sequential groups. Approximately 40 subjects will be enrolled into 5 planned dose level cohorts. Each dose level cohort will consist of 8 subjects; 6 subjects will receive CC-92480 and 2 subjects will receive placebo according to the randomization schedule. Part 2 Part 2 is a single-center, open-label, randomized, 2-period, 2-way crossover study to explore the effect of food (Food and Drug Administration [FDA] standard high-fat breakfast) on the single-dose PK of CC-92480 in healthy adult subjects.